CLINICAL_TRIALS
trial_result
· 2020-03-30
Clinical Trial Update: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer [Phase 2]
Summary
Phase 2 trial of docetaxel plus ARN-509 in castration-resistant prostate cancer was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-03-30